ARHGAP19 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ARHGAP19 gene in the well-characterized human HAP1 cell line. This loss-of-function model provides a robust tool for dissecting the cellular roles of ARHGAP19, particularly in the regulation of Rho GTPase signaling, cytokinesis, and cell migration. By employing a polyclonal format, the product retains genetic heterogeneity, avoiding biases associated with single-cell clones and enabling more representative phenotypic analyses. Researchers can utilize this resource to interrogate ARHGAP19 function across diverse experimental contexts, from targeted pathway investigation to genome-wide screens.
The HAP1 host cell line is a human near-haploid cell model derived from the chronic myelogenous leukemia line KBM-7. Its near-haploid karyotype, with only one copy of most chromosomes, greatly simplifies CRISPR/Cas9-mediated gene knockout, as a single successful editing event can result in a null phenotype. This characteristic reduces the complexity of generating loss-of-function models and enhances the efficiency of genetic screens. HAP1 cells maintain key features of human somatic cells, making them suitable for studying fundamental cellular processes, including cell division, signal transduction, and cancer biology, while offering practical advantages for high-throughput applications.
ARHGAP19 encodes a Rho GTPase-activating protein (GAP) that negatively regulates Rho family GTPases by accelerating their intrinsic GTP hydrolysis, thereby promoting the inactive GDP-bound state. Its primary targets include RhoA, Rac1, and Cdc42, critical regulators of actin cytoskeleton dynamics. ARHGAP19 is phosphorylated by CDK1 during mitosis, linking its activity to cell cycle progression. It interacts with the cytokinesis regulators ECT2 and Aurora B, and associates with microtubules, positioning it at a key intersection of the mitotic machinery and cytoskeletal remodeling. Mechanistically, ARHGAP19-mediated inactivation of RhoA and its downstream effector ROCK, as well as Rac1-PAK and Cdc42-WASF pathways, coordinates contractile ring formation, abscission, and cell migration.
In the HAP1 cellular context, ARHGAP19 knockout provides a genetically clean and experimentally tractable model system. The near-haploid background ensures that disruption of the single ARHGAP19 allele eliminates functional protein, facilitating the study of cytokinesis failure, binucleation, or altered migration without confounding genetic variables. The polyclonal population captures a spectrum of editing outcomes, reflecting the functional impact of gene disruption at the population level. This makes the model particularly valuable for unbiased screening approaches, such as synthetic lethality or drug sensitivity profiling, where clonal variation could obscure true biological effects. The system also supports detailed mechanistic dissection of ARHGAP19’s interactions with key mitotic and Rho pathway components.
Diverse research applications are enabled by this knockout product, including western blotting and RT-qPCR for expression validation, and immunofluorescence for assessing cytokinesis defects such as multinucleation or failed cleavage furrow formation. Rho GTPase activation assays quantify downstream signaling effects, while cell migration and invasion assays evaluate alterations in motility. Flow cytometry-based cell cycle analysis and RNA-seq transcriptomic profiling provide broader functional insights. These approaches support investigations into cell division disorders, cancer metastasis, and Rho GTPase signaling networks. For further technical details or to discuss custom project requirements, please contact Ascent Research.
